Acrivon Therapeutics Files 8-K on Director Changes and Compensation
Ticker: ACRV · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1781174
| Field | Detail |
|---|---|
| Company | Acrivon Therapeutics, Inc. (ACRV) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
TL;DR
Acrivon Therapeutics filed an 8-K for director changes and executive pay. Details TBD.
AI Summary
On March 4, 2024, Acrivon Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, though specific details on the compensation or financial figures are not provided in this summary.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is procedural, reporting on corporate governance and compensation, and does not contain immediate financial or operational risks.
Key Players & Entities
- Acrivon Therapeutics, Inc. (company) — Registrant
- March 4, 2024 (date) — Date of Report
- 001-41551 (other) — SEC File Number
- 82-5125532 (other) — IRS Employer Identification No.
- 480 Arsenal Way, Suite 100 (location) — Principal Executive Offices Address
- Watertown, Massachusetts (location) — Principal Executive Offices Location
- 02472 (other) — Principal Executive Offices Zip Code
- (617) 207-8979 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific details of these changes are not elaborated in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item information, but the specific terms and amounts of these arrangements are not detailed in the provided excerpt.
What is the primary purpose of this 8-K filing?
The primary purpose is to report current information under Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically concerning director and officer changes and compensation.
When was this report filed with the SEC?
This report was filed on March 4, 2024.
What is Acrivon Therapeutics, Inc.'s principal executive office address?
Acrivon Therapeutics, Inc.'s principal executive office is located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-04 08:15:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value ACRV The Nasdaq Stock Mar
Filing Documents
- d791106d8k.htm (8-K) — 26KB
- d791106dex991.htm (EX-99.1) — 10KB
- g791106g0302040558021.jpg (GRAPHIC) — 7KB
- 0001193125-24-056937.txt ( ) — 174KB
- acrv-20240304.xsd (EX-101.SCH) — 3KB
- acrv-20240304_lab.xml (EX-101.LAB) — 18KB
- acrv-20240304_pre.xml (EX-101.PRE) — 11KB
- d791106d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Exhibit Description 99.1 Press Release of the Company, dated March 4, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Dated: March 4, 2024 By: /s/ Peter Blume-Jensen Name: Peter Blume-Jensen, M.D., Ph.D. Title: Chief Executive Officer and President